NL-OMON31603
Completed
Phase 2
A Multicenter Phase II Study of Neoadjuvant Docetaxel, Cisplatin and Capecitabine and Protocolized Surgery in Resectable Gastric Cancer An IKZ-based phase II feasibility study - DoCCS
Jeroen Bosch Ziekenhuis0 sites50 target enrollmentTBD
Overview
- Phase
- Phase 2
- Intervention
- Not specified
- Conditions
- gastric cancer
- Sponsor
- Jeroen Bosch Ziekenhuis
- Enrollment
- 50
- Status
- Completed
- Last Updated
- last year
Overview
Brief Summary
No summary available.
Investigators
Eligibility Criteria
Inclusion Criteria
- •Ib\-IVa histological proven resectable gastric adenocarcinoma, including gastro\-oesophageal junction/cardia carcinoma Siewert 2 and 3
- •WHO \< or equal to 1
- •Age \> or equal to 18 years
- •No prior radio\- or chemotherapy conflicting with the treatment of gastric cancer
Exclusion Criteria
- •Ia gastric cancer
- •Other histological type than adenocarcinoma
- •Distant metastases
- •Inoperable patients
- •Previous or other current malignancies
- •Other current serious illness or medical conditions
- •Pregnant or lactating women
Outcomes
Primary Outcomes
Not specified
Similar Trials
Active, not recruiting
Not Applicable
A Multicenter Phase II Study of Neoadjuvant Docetaxel, Cisplatin and Capecitabine combined with Protocolized Surgery in Resectable Gastric Cancer - DoCCSEUCTR2007-007273-23-NLJeroen Bosch Hospital
Recruiting
Not Applicable
A study to investigate the feasibility of chemotherapy prior to surgery and protocolized surgery in resectable stomach cancer.Resectable/curable gastric cancerNL-OMON20157dr K. Bosscha, surgeondr J.F.M. Pruijt, oncologistdrs A.E. Dassen, resident in training for surgery50
Recruiting
Phase 2
eoadjuvant DOS treatment for advanced esophageal cancerJPRN-jRCTs041210023Kodera Yasuhiro45
Active, not recruiting
Phase 1
A Multicenter Phase II Clinical Trial of Neoadjuvant Trabectedin (Yondelis®) in Patients with Localized Myxoid / Round Cell Liposarcomaocalized myxoid / round cell liposarcoma previously untreated with chemotherapy or radiationMedDRA version: 9.1Level: LLTClassification code 10024630Term: Liposarcoma non-metastaticEUCTR2007-000035-25-FRPharma Mar, S.A.22
Active, not recruiting
Not Applicable
A Multicenter Phase II Clinical Trial of Neoadjuvant Trabectedin (YONDELIS®) in Patients with Localized Myxoid / Round Cell Liposarcomaocally advanced (Stage III) myxoid / round cell liposarcoma previously untreated with chemotherapy or radiationMedDRA version: 9.1Level: LLTClassification code 10024630Term: Liposarcoma non-metastaticEUCTR2007-000035-25-DEPharma Mar, S.A.22